AIM:To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stageⅢ/Ⅳgastric cancer.METHODS:A total of 53 stageⅢ/Ⅳg...AIM:To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stageⅢ/Ⅳgastric cancer.METHODS:A total of 53 stageⅢ/Ⅳgastric cancer patients were enrolled into the study and treated with neoadjuvant chemotherapy.Two of the cases were excluded.The program was as follows:75 mg/m2docetaxel and 85 mg/m2 oxaliplatin on day 1 and 1500mg/m2 fluorouracil on days 1 to 3 for three weeks.RESULTS:The tumour changes,postoperative remission rate,changes in the symptoms and adverse reactions were observed.The overall clinical efficacy(com-plete remission+partial remission)of the neoadjuvant chemotherapy was 62.7%.R0 radical resection was performed on 60.8%of the patients,with a remission rate(pathological complete response+pathological subtotal response+pathological partial response)of74.2%.The Karnofksy score improved in 42 cases.The toxicity reactions mostly included myelosuppression,followed by gastrointestinal mucosal lesions,nausea,vomiting and diarrhoea.CONCLUSION:Neoadjuvant chemotherapy consisting of docetaxel combined with oxaliplatin and fluorouracil is effective for stageⅢ/Ⅳgastric cancer.However,the treatment is associated with a high incidence of bone marrow suppression,which should be managed clinically.展开更多
Novel furoxan-based nitric oxide-releasing derivatives 6a-p of hydroxylcinnamic acids were synthesized by coupling the carboxyl group of hydroxylcinnamic acids with furoxan through various alkylol amines.Compounds 6a,...Novel furoxan-based nitric oxide-releasing derivatives 6a-p of hydroxylcinnamic acids were synthesized by coupling the carboxyl group of hydroxylcinnamic acids with furoxan through various alkylol amines.Compounds 6a,e-i and m-p displayed more potent anti-tumor activities superior to control 5-fluorouracil（5-FU） in most cancer cells tested.Furthermore,6f could selectively inhibit tumor cells,but not non-tumor cell proliferation.This inhibition was attributed to high levels of NO released in cancer cells and potentially synergistic effect of NO donor moieties and the bioactivity of hydroxylcinnamic acids.展开更多
文摘AIM:To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stageⅢ/Ⅳgastric cancer.METHODS:A total of 53 stageⅢ/Ⅳgastric cancer patients were enrolled into the study and treated with neoadjuvant chemotherapy.Two of the cases were excluded.The program was as follows:75 mg/m2docetaxel and 85 mg/m2 oxaliplatin on day 1 and 1500mg/m2 fluorouracil on days 1 to 3 for three weeks.RESULTS:The tumour changes,postoperative remission rate,changes in the symptoms and adverse reactions were observed.The overall clinical efficacy(com-plete remission+partial remission)of the neoadjuvant chemotherapy was 62.7%.R0 radical resection was performed on 60.8%of the patients,with a remission rate(pathological complete response+pathological subtotal response+pathological partial response)of74.2%.The Karnofksy score improved in 42 cases.The toxicity reactions mostly included myelosuppression,followed by gastrointestinal mucosal lesions,nausea,vomiting and diarrhoea.CONCLUSION:Neoadjuvant chemotherapy consisting of docetaxel combined with oxaliplatin and fluorouracil is effective for stageⅢ/Ⅳgastric cancer.However,the treatment is associated with a high incidence of bone marrow suppression,which should be managed clinically.
文摘Novel furoxan-based nitric oxide-releasing derivatives 6a-p of hydroxylcinnamic acids were synthesized by coupling the carboxyl group of hydroxylcinnamic acids with furoxan through various alkylol amines.Compounds 6a,e-i and m-p displayed more potent anti-tumor activities superior to control 5-fluorouracil（5-FU） in most cancer cells tested.Furthermore,6f could selectively inhibit tumor cells,but not non-tumor cell proliferation.This inhibition was attributed to high levels of NO released in cancer cells and potentially synergistic effect of NO donor moieties and the bioactivity of hydroxylcinnamic acids.
